JAK1 inhibitor Rinvoq (upadacitinib) approved by the FDA in the United States

Upadacitinib tartrate, a small-molecule selective inhibitor of JAK1, was recently approved in the U.S. as a treatment for adults with moderately to severely active rheumatoid arthritis (RA) and an inadequate response […]
Read More →